|
|
|
|
||
Building IP: BMY Patent Application re "SELECTIVE NR2B ANTAGONISTS"
SELECTIVE NR2B ANTAGONISTS The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. ##STR00001##
1. A pharmaceutical composition comprising the compound (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylben- zyl)pyrrolidin-2-one or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This Continuation application claims the benefit of U.S. Ser. No. 15/971,067 filed May 4, 2018, now pending, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 15/846,672 filed Dec. 19, 2017, now abandoned, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 15/706,172 filed Sep. 15, 2017, now abandoned, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 15/604,904 filed May 25, 2017, now abandoned, which in turn is a Continuation application claims the benefit of U.S. Ser. No. 14/882,041 filed Oct. 13, 2015, now abandoned, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 14/589,205 filed Jan. 5, 2015, now U.S. Pat. No. 9,221,796, which in turn is a Non-Provisional application which claims the benefit of Provisional application U.S. Ser. No. 61/925,363 filed Jan. 9, 2014, now expired, hereby incorporated by reference in their entireties. BACKGROUND OF THE INVENTION [0002] The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system. [0003] N-Methyl-D-aspartate (NMDA) receptors are ion channels which are gated by the binding of glutamate, an excitatory neurotransmitter in the central nervous system. They are thought to play a key role in the development of a number of neurological diseases, including depression, neuropathic pain, Alzheimer's disease, and Parkinson's disease. Functional NMDA receptors are tetrameric structures primarily composed of two NR1 and two NR2 subunits. The NR2 subunit is further subdivided into four individual subtypes: NR2A, NR2B, NR2C, and NR2D, which are differentially distributed throughout the brain. Antagonists or allosteric modulators of NMDA receptors, in particular NR2B subunit-containing channels, have been investigated as therapeutic agents for the treatment of major depressive disorder (G. Sanacora, 2008, Nature Rev. Drug Disc. 7: 426-437). [0004] The NR2B receptor contains additional ligand binding sites in addition to that for glutamate. Non-selective NMDA antagonists such as Ketamine are pore blockers, interfering with the transport of Ca.sup.++ through the channel. Ketamine has demonstrated rapid and enduring antidepressant properties in human clinical trials as an i.v. drug. Additionally, efficacy was maintained with repeated, intermittent infusions of Ketamine (Zarate et al., 2006, Arch. Gen. Psychiatry 63: 856-864). This class of drugs, though, has limited therapeutic value because of its CNS side effects, including dissociative effects. [0005] An allosteric, non-competitive binding site has also been identified in the N-terminal domain of NR2B. Agents which bind selectively at this site, such as Traxoprodil, exhibited a sustained antidepressant response and improved side effect profile in human clinical trials as an i.v. drug (Preskorn et al., 2008, J. Clin. Psychopharmacol., 28: 631-637, and F. S. Menniti, et al., 1998, CNS Drug Reviews, 4, 4, 307-322). However, development of drugs from this class has been hindered by low bioavailability, poor pharmacokinetics, and lack of selectivity against other pharmacological targets including the hERG ion channel. Blockade of the hERG ion channel can lead to cardiac arrhythmias, including the potentially fatal Torsades de pointe, thus selectivity against this channel is critical. Thus, in the treatment of major depressive disorder, there remains an unmet clinical need for the development of effective NR2B-selective negative allosteric modulators which have a favorable tolerability profile. [0006] NR2B receptor antagonists have been disclosed in PCT publication WO 2009/006437. [0007] The invention provides technical advantages, for example, the compounds are novel and are ligands for the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability. |
return to message board, top of board |